share_log
Benzinga ·  Jan 29 13:30
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Completion Enables the End-of-Phase 2 (EOP2) Interaction With the FDA on the Design of the Phase 3 Program and Is Expected to Facilitate Ongoing Partnership Discussions'
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 329

Recommended

Write a comment